Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Castle Biosciences Inc (NQ: CSTL )

28.88 +0.43 (+1.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023
From Castle Biosciences, Inc.
Via Business Wire
Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
Looking Into Castle Biosciences's Return On Capital Employed
Via Benzinga
Castle Biosciences: Q2 Earnings Insights
  Castle Biosciences (NASDAQ:CSTL) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory
From Castle Biosciences, Inc.
Via Business Wire
Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year
From Castle Biosciences, Inc.
Via Business Wire
This Analyst With 90% Accuracy Rate Raises PT On Chesapeake Energy; Here Are 5 Stock Picks For Last Week From Benzinga's Most Accurate Analysts
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes... 
Via Benzinga
This Analyst With 82% Accuracy Rate Boosts PT On Booking Holdings; Here Are 5 Stock Picks For Thursday From Benzinga's Most Accurate Analysts
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes... 
Via Benzinga
Castle Biosciences Announces Third Quarter 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present at Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via Business Wire
Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
From Castle Biosciences, Inc.
Via Business Wire
New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
From Castle Biosciences, Inc.
Via Business Wire
New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2
From Castle Biosciences, Inc.
Via Business Wire
Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q2, Castle Biosciences's (NASDAQ:CSTL) reported sales totaled $34.84 million. Despite a 93.31% increase in earnings, the company posted a loss of $1.65... 
Via Benzinga
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Host Investor Day on Sept. 20, 2022
From Castle Biosciences, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.